02Sep
19Jul
Drug for concussion, stroke found by UT scientist moves closer to human trials
Astrocyte Pharmaceuticals, the company Lechleiter founded with William Korinek of Boston, completed Monday its first round of financing that raised roughly $2.4 million in fresh capital. The fledgling company had $670,000 in seed funding from the federal government since 2014. Lechleiter hopes the drug, which is at least 7 years away from market, could be easily administered by any football coach or paramedic to mitigate the effects of concussions or strokes. Read more >>
28Mar
Boston Harbor Angels Bet on New Frontier in Neuroscience
Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson's Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly. Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI,...
25Mar